Lipoprotein apheresis of hypercholesterolemic patients mediates vasoprotective gene expression in human endothelial cells

Morawietz, Henning; Göettsch, Winfried; Brux, Melanie; Reimann, Manja; Bornstein, Stefan R.; Julius, Ulrich; Ziemssen, Tjalf

doi:10.1016/j.atherosclerosissup.2012.10.013

Cited by 17 publications

(9 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Both systems, however, were similarly efficient at reducing E-selectin levels. Our results are consistent with previous studies, in which significant reductions in E-selectin were observed with both HELP and DS [11], but our results contrast with other findings showing significant reductions in ICAM-1 and VCAM-1 levels following LA [11,41,42]. Sampietro et al reported a significant reduction in the ICAM-1 and E-selectin levels in FH subjects following LA with DS and suggested that cholesterol could play a major role in controlling adhesion molecule levels because adsorption of these two molecules to the DS columns was negligible [43].…”

Section: Discussionsupporting

confidence: 91%

Comparison of two low‐density lipoprotein apheresis systems in patients with homozygous familial hypercholesterolemia

Drouin‐Chartier

Tremblay

Bergeron

et al. 2015

J of Clinical Apheresis

View full text Add to dashboard Cite

Low-density lipoprotein (LDL) apheresis (LA) is a reliable method to decrease LDL-C concentrations and remains the gold standard therapy in homozygous familial hypercholesterolemia (HoFH). The objective of this study was to compare the efficacy of two LA systems [heparin-induced extracorporeal LDL precipitation (HELP) vs. dextran sulfate adsorption (DS) on the reduction of lipids, inflammatory markers, and adhesion molecules in a sample of genetically defined HoFH subjects (n = 9)]. Fasting blood samples were collected before and after LA. All subjects served as their own control and were first treated with the HELP system then with DS in this single sequence study. Compared with HELP, DS led to significantly greater reductions in total cholesterol (-63.3% vs. -59.9%; P = 0.05), LDL-C (-70.5% vs. -63.0%; P = 0.02), CRP (-75.3% vs. -48.8%; P < 0.0001), and TNF-α (-23.7% vs. +14.7%; P = 0.003). Reductions in the plasma levels of PCSK9 (-45.3% vs. -63.4%; P = 0.31), lipoprotein (a) (-70.6% vs. -65.0%; P = 0.30), E-selectin (-16.6% vs. -18.3%; P = 0.65), ICAM-1 (-4.0 vs. 5.6%; P = 0.56), and VCAM-1 (8.3% vs. -1.8%; P = 0.08) were not different between the two systems. For the same volume of filtered plasma (3,000 mL), however, HELP led to greater reductions in plasma apoB (-63.1% vs. -58.3%; P = 0.04), HDL-C (-20.6% vs. -6.5%; P = 0.003), and PCSK9 (-63.4% vs. -28.5%; P = 0.02) levels. These results suggest that both LA systems are effective in reducing plasma lipids and inflammatory markers in HoFH. Compared with HELP, greater reductions in lipid levels and inflammatory markers were achieved with DS, most likely because this method allows for a larger plasma volume to be filtered. J. Clin. Apheresis 31:359-367, 2016. © 2015 Wiley Periodicals, Inc.

show abstract

Section: Discussionsupporting

confidence: 91%

Comparison of two low‐density lipoprotein apheresis systems in patients with homozygous familial hypercholesterolemia

Drouin‐Chartier

Tremblay

Bergeron

et al. 2015

J of Clinical Apheresis

View full text Add to dashboard Cite

show abstract

“…These properties of HDL can be examined by measuring NO production by fluorescence in cell culture systems [166] . HDL effects on eNOS activation can be measured by quantifying the ratio of ser1177/thr495 phosphorylation [166] , [167] , [168] . Data from this assay have consistently demonstrated the ability of HDL to modulate eNOS expression and NO production [10] , [11] , [158] .…”

Section: Hdl Functional Assaysmentioning

confidence: 99%

“…The expression of intercellular adhesion molecules (ICAMs) and vascular cell adhesion molecule-1 (VCAM-1) that forms vascular endothelial cell in response to an inflammatory stimulus (via nuclear factor κB — NF-κB) can be modulated by HDL [13] , [173] ( Table 3 ). The peptides can be measured in plasma by ELISA or gel separation techniques [13] , [168] and provide a biomarker of vascular inflammatory state. The effect of HDL on endothelial progenitor cells (EPC) had been examined in an in-vivo system of carotid denudation in the athymic nude mouse.…”

Section: Hdl Functional Assaysmentioning

confidence: 99%

High density lipoproteins: Measurement techniques and potential biomarkers of cardiovascular risk

2015

View full text Add to dashboard Cite

Plasma high density lipoprotein cholesterol (HDL) comprises a heterogeneous family of lipoprotein species, differing in surface charge, size and lipid and protein compositions. While HDL cholesterol (C) mass is a strong, graded and coherent biomarker of cardiovascular risk, genetic and clinical trial data suggest that the simple measurement of HDL-C may not be causal in preventing atherosclerosis nor reflect HDL functionality. Indeed, the measurement of HDL-C may be a biomarker of cardiovascular health. To assess the issue of HDL function as a potential therapeutic target, robust and simple analytical methods are required. The complex pleiotropic effects of HDL make the development of a single measurement challenging. Development of laboratory assays that accurately HDL function must be developed validated and brought to high-throughput for clinical purposes. This review discusses the limitations of current laboratory technologies for methods that separate and quantify HDL and potential application to predict CVD, with an emphasis on emergent approaches as potential biomarkers in clinical practice.

show abstract

“…Dihazi et al compared serum samples by proteomic analysis before and after LDL apheresis [ 17 ] and they found significant depletion of more than 70 functional proteins including peptides that were involved in the coagulation system and that with adhesive, rheological and inflammatory actions. They concluded that there was a strong interaction between the column and serum proteins during treatment, while others found altered gene expression of various molecules after the apheresis [ 18 – 20 ].…”

Section: Discussionmentioning

confidence: 99%

Impact of selective LDL apheresis on serum chemerin levels in patients with hypercholesterolemia

et al. 2016

View full text Add to dashboard Cite

BackgroundSelective low-density lipoprotein (LDL) apheresis is commonly used to treat patients with familial hypercholesterolemia (FH). Chemerin is an adipokine with putative roles in the regulation of lipid metabolism.MethodsIn our pilot study, we measured serum chemerin levels by enzyme-linked immunosorbent assay in six severe heterozygous FH patients before and after their first LDL apheresis treatments using the technique of direct adsorption of lipoproteins (DALI).ResultsThe first treatment sessions decreased serum chemerin levels by an average of 27.26 %. While following one patient, 12 months of regular LDL apheresis resulted in a permanent reduction in his serum chemerin level. Changes in the lipoprotein subfractions measured by gel electrophoresis (Lipoprint) correlated with the reduction of chemerin levels. Furthermore, we eluted and then measured chemerin bound to the DALI column.ConclusionWe conclude that LDL apheresis decreases the circulating level of chemerin by binding the protein to the column and thus improves lipoprotein subfraction pattern.

show abstract

Lipoprotein apheresis of hypercholesterolemic patients mediates vasoprotective gene expression in human endothelial cells

Cited by 17 publications

References 41 publications

Comparison of two low‐density lipoprotein apheresis systems in patients with homozygous familial hypercholesterolemia

Comparison of two low‐density lipoprotein apheresis systems in patients with homozygous familial hypercholesterolemia

High density lipoproteins: Measurement techniques and potential biomarkers of cardiovascular risk

Impact of selective LDL apheresis on serum chemerin levels in patients with hypercholesterolemia

Contact Info

Product

Resources

About